Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer.

Autor: Ladjevardi CO; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden., Skribek M; Thoracic Oncology Center, Theme Cancer, Karolinska University Hospital, 171 76, Stockholm, Sweden.; Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden., Koliadi A; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden., Rydén V; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden., El-Naggar AI; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Digkas E; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Mälarsjukhuset, 633 49, Eskilstuna, Sweden., Valachis A; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. antonios.valachis@oru.se., Ullenhag GJ; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Nov 07; Vol. 74 (1), pp. 14. Date of Electronic Publication: 2024 Nov 07.

The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis.

Autor: Rydén V; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden., El-Naggar AI; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.; Department of Oncology, Örebro University Hospital, Örebro, Sweden., Koliadi A; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden., Ladjevardi CO; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden., Digkas E; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.; Department of Oncology, Eskilstuna, Sweden., Valachis A; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.; Department of Oncology, Örebro University Hospital, Örebro, Sweden., Ullenhag GJ; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.

Publikováno v: Pigment cell & melanoma research [Pigment Cell Melanoma Res] 2024 May; Vol. 37 (3), pp. 352-362. Date of Electronic Publication: 2023 Dec 29.

988O A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma

Autor: Hamid, O., Rydén, V., Mehmi, I., Wang, D., Patel, M., Krause, J., Sandin, L.C., Grauers Wiktorin, H., Lövgren, T., Eriksson, E., Leja Jarblad, J., Loskog, A., Ullenhag, G.J.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S674-S674

Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.

Autor: Olsson Ladjevardi C; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden., Koliadi A; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden., Rydén V; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden., Inan El-Naggar A; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Digkas E; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Mälarsjukhuset, Eskilstuna, Sweden., Valachis A; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Ullenhag GJ; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.

Publikováno v: Cancer medicine [Cancer Med] 2023 Jun; Vol. 12 (12), pp. 13217-13224. Date of Electronic Publication: 2023 May 03.

Scalable Generation of Pre‐Vascularized and Functional Human Beige Adipose Organoids.

Autor: Escudero, Mélanie^1,2 (AUTHOR), Vaysse, Laurence¹ (AUTHOR), Eke, Gozde² (AUTHOR), Peyrou, Marion³ (AUTHOR), Villarroya, Francesc³ (AUTHOR), Bonnel, Sophie¹ (AUTHOR), Jeanson, Yannick¹ (AUTHOR), Boyer, Louisa² (AUTHOR), Vieu, Christophe² (AUTHOR), Chaput, Benoit⁴ (AUTHOR), Yao, Xi⁵ (AUTHOR), Deschaseaux, Frédéric¹ (AUTHOR), Parny, Mélissa^1,6 (AUTHOR), Raymond‐Letron, Isabelle^1,6 (AUTHOR), Dani, Christian⁵ (AUTHOR), Carrière, Audrey¹ (AUTHOR), Malaquin, Laurent² (AUTHOR), Casteilla, Louis¹ (AUTHOR) louis.casteilla@inserm.fr

Publikováno v: Advanced Science. 11/3/2023, Vol. 10 Issue 31, p1-20. 20p.